This is the mail archive of the ecos-bugs@sources.redhat.com mailing list for the eCos project.


Index Nav: [Date Index] [Subject Index] [Author Index] [Thread Index]
Message Nav: [Date Prev] [Date Next] [Thread Prev] [Thread Next]
Other format: [Raw text]

lifesaving tech. BioTech Alert for Mon.


BIOTECHNOLOGY NEWS.....  MONDAY JULY 25 WATCH
. RADAR ALERT ....RADAR ALERT.....RADAR ALERT.....RADAR ALERT


Pacific Sunset Investments Inc.
SYMBOL: PSIV
CURRENT PRICE: .24
SHORT-TERM:  $1.00

How many times have you heard about this????
adverse drug reactions accounted for more than 2.2 million serious cases and
over 100,000 deaths,

PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV

A study published in the Journal of the American Medical Association
reported that adverse drug reactions accounted for more than 2.2 million
serious cases and over 100,000 deaths, making adverse drug reactions (ADRs)
one of the leading causes of hospitalization and death in the United States.

Breaking News for Pacific Sunset Investments

Pacific Sunset Investments Completes Gen ID Acquisition
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--May 20, 2005--Pacific Sunset
Investments, Inc. ("Pacific Sunset") (OTC:PSiV announced that it has
completed its acquisition of Gen-ID Lab Services, LLC, a California limited
liability corporation specializing in Single Nucleotide Polymorphism
analysis data. In addition, the board of directors of Pacific Sunset has
appointed Douglas Freedman to its board of directors with experience in
marketing. Additionally, the company has appointed Dr. Steve N. Slilaty,
Ph.D., to head an Advisory Board to assist the company with reviewing new
alternatives in the "SNP" field of technology.

Gen ID will provide "SNP" (Single Nucleotide Polymorphism) analysis data.
The results of SNP analysis provide physicians with a more enlightened
choice of drugs and they will also be able to predict the effectiveness of
the drugs for individual patients. The use of an SNP test to help treat
childhood leukemia is currently being used by doctors and hospitals in the
United States.

Dr. Steve Slilaty is President and Chief Scientific Officer of Advanomics
Corporation, a leading-edge biotechnology company focusing on the
identification of disease related molecular targets using advanced
transriptomics technologies, which he recently developed. Dr. Slilaty also
is an Adjunct Professor at the Universite du Quebec in the department of
Microbiology and Biotechnology. Dr. Slilaty has founded three biotechnology
companies, Advanomics Corporation, Quantum Biotechnologies Inc. (now known
as Qbiogene Inc.) and Geneomics One Corporation. In addition, Dr. Slilaty is
one of the pioneers of Gene Therapy, having developed the first Gene
Transfer system in 1983.

(This is a partial clip of the news.  We suggest you go read the whole
release.  Our opinion is, this is important technology.  Go to yahoo or any
financial site and read the news)

CONCLUSION:
adverse drug reactions accounted for more than 2.2 million serious cases and
over 100,000 deaths,  Doesn't this say it all?

 A company to watch!

AGGRESSIVE INVESTORS TAKE NOTE NOW!
PUT Pacific Sunset Investments Inc. PSiV
ON YOUR RADAR SCREENS NOW,
AND WATCH THIS COMPANY STARTING NOW

Disclaimer:
Information within this email contains "forwardlooking statements" within
the meaning of Section 27Aof the Securities Act of 1933 and Section 21B of
the Securities Exchange Act of 1934. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements". "Forward looking statements" are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as "projects", "foresee", "expects", "will", "anticipates",
"estimates", "believes", "understands" or that by statements indicating
certain actions "may", "could", or "might" occur. Risk factors include
general economic and business conditions, the ability to acquire and develop
specific projects, the ability to fund operations and changes in consumer
and business consumption habits and other factors overwhich the company has
little or no control. The publisher of this newsletter does not represent
that the information contained in this message states all material facts or
does not omit a material fact necessary to make the statements therein not
misleading. All information provided within this email pertaining to
investing, ST0CKs, securities must be understood as information provided and
not investment advice. The publisher of this newsletter advises all readers
and subscribers to seek advice from a registered professional securities
representative before deciding to trade in ST0CKs featured within this
email. None of the material within this report shall be construed as any
kind of investment advice or solicitation. Many of these companies are on
the verge of bankruptcy. You can lose all your money by investing in this
ST0CK. We urge you to read the company's SEC filings now, before you invest.
The publisher of this newsletter is not a registered invstment advisor.
Subscribers should not view information herein as legal, tax, accounting or
investment advice. In compliance with the SecuritiesAct of 1933, Section
17(b), The publisher of this newsletter is contracted to receive six hundred
thousand free trading shares from a third party, not an officer, director or
affiliate shareholder for the circulation of this report. Be aware of an
inherent conflict of interest resulting from such compensation due to the
fact that this is a paid advertisement and is not without bias. The party
that paid us has a position in the ST0CK they will sell at anytime without
notice. This could have a negative impact on the price of the ST0CK, causing
you to lose money. All factual information in this report was gathered from
public sources, including but not limited to SEC filings, Company Websites
and Company Press Releases. The publisher of this newsletter believes this
information to be reliable but can make no guarantee as to its accuracy or
completeness. Use of the material within this email constitutes your
acceptance of these terms.

detonated himself Three people were killed and 38 
woundedIn alKadhimiya in central Baghdad an Iraqi police 
car was attacked by a rocketpropelled grenade and 
the US military was
called in When the American troops were on 
the scene a suicide bomber boarded a bus 
of pilgrims and detonated v himself The attack killed 
a US soldier three policemen and a civilian v 
Twentytwo civilians were woundedPolice 
said that in alWaziriya in northern Baghdad three 
people launched suicide attacks One detonated killing an 
Iraqi soldier The second as Unity Day when v 
insurgents can voluntarily surrender The Baquba blast happened 
just 500 yards meters from where a Unity 
Day event was set to be held a 
few hours laterUnity Day was established by the 
US military as an incentive to insurgents and 
Baathists to stop their 

attacks The regional grouping Ecowas said Mr Faure's 
promise to hold elections within 60 days was 
not enough The sanctions include suspension from Ecowas 
the recall of ambassadors 
from Togo a travel ban on the Togolese 
leadership and an arms embargo The African Union 
has also condemned Mr Gnassingbe's refusal to leave 
was speaking after meeting a highlevel Togolese delegation 
in Nigeria Rival rallies Under the original constitution 
which was amended to legitimise Mr Faure's installation v
the parliamentary speaker should hold the presidency pending 
the election The opposition wants the new leader v v 
to step down immediately In Togo itself rival v v 
demonstrations by critics and 

Index Nav: [Date Index] [Subject Index] [Author Index] [Thread Index]
Message Nav: [Date Prev] [Date Next] [Thread Prev] [Thread Next]